2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-103566
    LY456236 338736-46-2 ≥99.0%
    LY456236 is a selective, non-competitive and orally active mGlu1 receptor antagonist that inhibits phosphoinositide hydrolysis with an IC50 of 0.145 μM. LY456236 also inhibits EGFR with an IC50 of 0.91 μM.
    LY456236
  • HY-103568
    YM-298198 hydrochloride 1216398-09-2 ≥99.0%
    YM-298198 hydrochloride is a high-affinity, selective, orally active, and non-competitive antagonist of metabotropic glutamate receptor type 1 (mGluR1). YM-298198 hydrochloride can be used for the research of neurological disorders.
    YM-298198 hydrochloride
  • HY-103572
    MNI137 946619-21-2
    MNI137 is a potent and selective negative allosteric modulator for group II mGluRs. MNI137 has IC50s values of 8.3 and 12.6 nM for human and rat mGlu2 inhibition of glutamate-induced calcium mobilization.
    MNI137
  • HY-103664
    Fmoc-1,6-diaminohexane 166410-37-3 99.29%
    Fmoc-1,6-diaminohexane is an analog of Osw-1 which has the potential for Alzheimer's disease and cancer treatment from patent US 20140135279 A1.
    Fmoc-1,6-diaminohexane
  • HY-105584
    Tolycaine 3686-58-6 99.13%
    Tolycaine is a local agent that can suppress or relieve pain. Tolycaine also induces a convulsive response in experimental animals.
    Tolycaine
  • HY-106094
    CY 208-243 100999-26-6 99.98%
    CY 208-243 is a selective dopamine D1 receptor agonist which exhibits antiparkinsonian activity.
    CY 208-243
  • HY-107094
    MT-7716 hydrochloride 1215859-93-0 99.06%
    MT-7716 hydrochloride (W-212393 hydrochloride) is a selective non-peptide nociceptin receptor (NOP) agonist and promising potential treatment drug for alcohol abuse and relapse prevention.
    MT-7716 hydrochloride
  • HY-107319
    Almitrine mesylate 29608-49-9 99.81%
    Almitrine mesylate, a peripheral chemoreceptor agonist, inhibits selectively the Ca2+-dependent K+ channel.
    Almitrine mesylate
  • HY-107508
    VU-29 890764-36-0 99.63%
    VU-29 is a positive allosteric modulator of metabotropic glutamate 5 (mGlu5) receptor (EC50=9 nM and Ki=244 nM for rmGluR5). VU-29 is selective for mGluR5 relative to other mGluR subtypes (EC50: rmGluR1/rmGluR2=557 nM/1.5 μM; hmGluR4=154 nM).
    VU-29
  • HY-107509
    LY2389575 hydrochloride 885104-09-6 99.93%
    LY2389575 hydrochloride is a selective and noncompetitive mGlu3 negative allosteric modulator (NAM), with an IC50 value of 190 nM. LY2389575 hydrochloride induces an increase in Mrc1 levels. LY2389575 hydrochloride also independently amplifies Amyloid beta (Aβ) toxicity and can be used in study of Alzheimer's disease.
    LY2389575 hydrochloride
  • HY-107514
    (RS)-PPG 120667-15-4
    (RS)-PPG is a potent and selective agonist for group III mGluRs. The EC50s of 5.2 μM, 4.7 μM, 185 μM, and 0.2 μM for hmGluR4a, hmGluR6, hmGluR7b, and hmGluR8a, respectively. Anticonvulsive and neuroprotective activity.
    (RS)-PPG
  • HY-107624
    ATC0175 510733-97-8 99.84%
    ATC0175 is a potent, selective and orally active melanin-concentrating hormone 1 recepter antagonist with IC50s of 13.5, >10000 nM for MCH1R, MCH2R, respectively. ATC0175 shows antidepressant effects and anxiolytic effects in animal models. ATC0175 has the potential for the research of depression and/or anxiety disorders.
    ATC0175
  • HY-107654
    Muscarine iodide 24570-49-8
    Muscarine ((+)-Muscarine) iodide is a toxin that can stimulate the parasympathetic nervous system. Muscarine iodide is a prototype muscarinic acetylcholine receptor agonist.
    Muscarine iodide
  • HY-107733
    NTNCB hydrochloride 191931-56-3 98.36%
    NTNCB (Compound 11) hydrochloride is a potent and selective neuropeptide Y Y5 (NPY Y5) receptor antagonist with a Ki of 8 nM against human Y5.
    NTNCB hydrochloride
  • HY-107735
    CYM 9484 1383478-94-1 99.43%
    CYM 9484 is a selective and highly potent neuropeptide Y (NPY) Y2 receptor antagonist with an IC50 value of 19 nM.
    CYM 9484
  • HY-108038
    ABT-107 855291-54-2 99.73%
    ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.
    ABT-107
  • HY-108069
    Iptakalim hydrochloride 642407-63-4 ≥98.0%
    Iptakalim hydrochloride, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (KATP) opener, as well as an α4β2-containing nicotinic acetylcholine receptor (nAChR) antagonist.
    Iptakalim hydrochloride
  • HY-108237
    Naxagolide 88058-88-2 99.81%
    Naxagolide ((+)-PHNO; Dopazinol) is a potent dopamine D2 (Dopamine Receptor) agonist. Naxagolide has the potential for the research of parkinson's disease (PD).
    Naxagolide
  • HY-108316
    Sultiame 61-56-3 ≥98.0%
    Sultiame is a carbonic anhydrase inhibitor, widely used as an antiepileptic agent.
    Sultiame
  • HY-108328
    Nerigliatin 1245603-92-2 ≥98.0%
    Nerigliatin (PF-04937319) is a orally active glucokinase activator (GKA) with EC50 value of 154.4 μM. Nerigliatin maintains glucose-lowering efficacy. Nerigliatin causes peripheral nerve degeneration. Nerigliatin can be used in type 2 diabetes research.
    Nerigliatin
Cat. No. Product Name / Synonyms Application Reactivity